Can larotrectinib shrink tumors?

The main effect of Larotrectinib (Larotrectinib) is to inhibit the growth and spread of TRK (neuronal growth factor receptor) gene fusion-positive tumors, rather than directly shrinking tumors. TRKGene fusion is a rare genetic abnormality that can cause a variety of cancers.

Larotrectinib helps control tumor growth by interfering with the activity of the TRK fusion protein and preventing it from transmitting growth signals in tumor cells. This drug is often used to treat patients with TRK gene fusion-positive tumors, especially those that cannot be removed by surgery or have distant metastases.

Although larotrectinib cannot directly shrink tumors, it can effectively inhibit tumor growth, slow down disease progression, and improve patients' quality of life. During treatment, doctors typically monitor the size and condition of the tumor regularly to make sure the drugs are still effective and adjust the treatment plan as needed.

In summary, the main goal of larotrectinib is to control the progression ofTRK gene fusion-positive tumors rather than directly shrink tumors. Patients should closely follow their doctor's advice when using this medication and have regular checkups to ensure optimal treatment results.

Larotrectinib has been launched in China, but it has not been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in China. Please consult the local hospital pharmacy for details. There are original drugs and generic drugs of larotrectinib abroad. The original drugs include German version, American version, European version and Hong Kong version. The price is basically around 20,000 yuan. Generic drugs include Lao and Bangladeshi versions, with prices ranging from two to three thousand. The ingredients of original drugs and generic drugs are basically the same.